Arcus Biosciences (RCUS) Stock Price, News & Analysis

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RCUS shares.
View RCUS analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued 1-year target prices for Arcus Biosciences' stock. Their RCUS share price targets range from $23.00 to $70.00. On average, they predict the company's stock price to reach $41.25 in the next year. This suggests a possible upside of 182.7% from the stock's current price.
View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts.

Arcus Biosciences' stock was trading at $19.10 on January 1st, 2024. Since then, RCUS stock has decreased by 23.6% and is now trading at $14.59.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RCUS earnings forecast.

Arcus Biosciences, Inc. (NYSE:RCUS) posted its earnings results on Wednesday, February, 21st. The company reported ($1.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.01. The business earned $31 million during the quarter, compared to analyst estimates of $28.30 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 57.17% and a negative net margin of 262.39%. The business's revenue for the quarter was down 8.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.93) earnings per share.

ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and ALPS Medical Breakthroughs ETF (SBIO).Invesco S&P SmallCap Health Care ETF (PSCH).

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD).

Arcus Biosciences (RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Arcus Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.01%), Diversified Trust Co (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends.

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.